Literature DB >> 12057033

Sequential catecholamine and serotonin depletion in mirtazapine-treated depressed patients.

Pedro L Delgado1, Francisco A Moreno, Larry Onate, Alan J Gelenberg.   

Abstract

This study was aimed at determining whether patient- or antidepressant-related variables are most important to the mood response to serotonin (5-HT) or catecholamine depletion. Depressed patients treated with open-label mirtazapine (>or=6 wk) received two depletion tests (5-HT and catecholamine depletion) 1 wk apart. Both 5-HT and catecholamine depletion led to a partial return of depression in most patients. Antidepressant response to mirtazapine is dependent on its dual actions on norepinephrine and 5-HT neurotransmission. Mood response to tryptophan or catecholamine depletion is dependent on the pharmacological properties of the antidepressant being taken during depletion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12057033     DOI: 10.1017/S1461145702002778

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  7 in total

1.  A new strategy for antidepressant prescription.

Authors:  Francis Lavergne; Thérèse M Jay
Journal:  Front Neurosci       Date:  2010-11-19       Impact factor: 4.677

Review 2.  Serotonin and beyond: therapeutics for major depression.

Authors:  Pierre Blier; Mostafa El Mansari
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-25       Impact factor: 6.237

Review 3.  Mirtazapine: a review of its use in major depression and other psychiatric disorders.

Authors:  Katherine F Croom; Caroline M Perry; Greg L Plosker
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

4.  Serotonin transporter genotype and depressive phenotype determination by discriminant analysis of glucose metabolism under acute tryptophan depletion.

Authors:  Allison C Nugent; Alexander Neumeister; David Goldman; Peter Herscovitch; Dennis S Charney; Wayne C Drevets
Journal:  Neuroimage       Date:  2008-07-30       Impact factor: 6.556

5.  All the right moves: the need for the timely use of hyperbaric oxygen therapy for treating TBI/CTE/PTSD.

Authors:  Kenneth P Stoller
Journal:  Med Gas Res       Date:  2015-05-28

6.  Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant?

Authors:  Roger M Pinder
Journal:  Neuropsychiatr Dis Treat       Date:  2005-03       Impact factor: 2.570

7.  Onset of improvement and response to mirtazapine in depression: a multicenter naturalistic study of 4771 patients.

Authors:  Francis Lavergne; Ivan Berlin; Alex Gamma; Hans Stassen; Jules Angst
Journal:  Neuropsychiatr Dis Treat       Date:  2005-03       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.